

Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with *mda-7/IL-24* Gene

Jingjing Luo, Qingmei Xia, Rui Zhang, Chen Lv, Wei Zhang, Yingxin Wang, Qiang Cui, Li Liu, Rong Cai, and Cheng Qian

Abstract Purpose: Recent studies showed that oncolytic adenoviruses not only have capacity for destruction of tumors but also can be used as potential vectors to express therapeutic genes for therapy of cancer. However, better specificity and mode of transgene expression are required to improve the efficacy and safety if this vector is applied for clinical application.

Experimental Design: In this study, we have created adenoviral replication-based transgene expression system by replacement of 6.7K/gp19K of E3 genes with *EGFP* and *IL-24* genes so that expression of transgenes should be controlled by adenoviral E3 promoter. Transgene expression, viral replication capacity, and cytotoxicity have been studied in tumor and normal cells. Antitumor efficacy was evaluated in animal model with established tumor.

Results: Our data showed that expression of IL-24 could be detected at 6 h and reached the maximal level at 48 h after infection in tumor cells. The expression level was 14 times higher than that induced by cytomegalovirus promoter. Low level of IL-24 could be detected in normal cells only until 72 h after infection. The substitution of 6.7K/gp19K of E3 genes with transgenes did not affect viral replication in tumor cells. Strong cytotoxicity was observed only in tumor cells after infection with AdCN205-IL-24. Treatment of the established tumors induced high level of local expression of IL-24 in tumor cells and resulted in tumor regression.

Conclusions: Our data showed that AdCN205-IL-24 can provide potent and safe vector for the therapy of cancer.

Cancer gene therapy by delivery of genetic material into tumor cells with therapeutic benefit provides great promise against cancer. Replication-defective viral vectors have been used for different applications for gene therapy of cancers. However, because of limitations involving vector delivery and relatively low levels of gene transfer, such vector systems have proven relatively inefficient for the treatment of large solid tumors (1–3). Conditionally replicative adenoviruses exert intrinsic antitumor activity through selective replication in lysis cancer cells. In addition, the release of conditionally replicative adenovirus progeny by infected tumor cells provides a potential to amplify the oncolytic effect by lateral spread through solid tumors (4–6). The clinical data showed that oncolytic adenovirus exhibited some degree of antitumor activity alone or combined with chemotherapy or radiotherapy (7–10).

The oncolytic viruses not only have capacity for destruction of tumors but also can be used as potential vectors to express therapeutic genes in tumor cells (11). Genes coding for tumor necrosis factor-related apoptosis-inducing ligand, second mitochondria-derived activator of caspases (Smac), Fas ligand, granulocyte macrophage colony-stimulating factor, and *mda-7/IL-24* have been incorporated into oncolytic adenovirus. The tumor regression was observed in animal models with established tumor after treatment with these vectors (12–19). However, in most of these constructs, therapeutic genes were controlled by exogenous constitutive promoters. Therefore, expression of therapeutic genes in normal tissue may induce undesired effect, and even oncolytic adenovirus does not replicate in it. On the other hand, inappropriate expression of therapeutic genes with cytotoxicity during viral replication cycle may impair viral replication efficacy (20, 21). The viral replication may turn off cellular or therapeutic gene expression because adenoviral replication has been attributed to a block in cytoplasmic accumulation of cellular mRNAs and preferential translation of viral mRNA (22, 23). Therefore, transgenes controlled by exogenous promoter may lead to unpredictable expression of the foreign genes over the course of the viral infection.

In contrast to the use of exogenous promoter for controlling therapeutic genes in oncolytic adenoviruses, recent studies have explored whether adenoviral endogenous promoters could be used for controlling therapeutic gene expression (24–28). Because both E3 genes or fiber genes are only expressed during replication cycle after infection of adenovirus (29, 30), it would

Authors' Affiliation: Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, Zhejiang, China
Received 10/10/07; revised 11/28/07; accepted 11/28/07.


Grant support: 973 Project (No. 2004CB518804), 863 Project (2006AA02Z126), and Zhejiang Province Grant (No. 2006C23006).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Cheng Qian, Institute of Medicine and Biotechnology, School of Life Science, Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018, China. Phone: 86-571-86843182; Fax: 86-571-86843185; E-mail: cqian3184@yahoo.com.cn.

©2008 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-07-4596

Fig. 1. Schematic structure of AdCN103, AdCN205-EGFP, and AdCN205-IL-24. In AdCN103, the E1A promoter was replaced by hTERT promoter and deletion of the adenoviral genome 923 to 946 nucleotides, which enables viral replication within malignant cells with abnormal retinoblastoma functions. In AdCN205-EGFP and AdCN205-IL-24, E3 6.7K/gp19K genes were substituted by *EGFP* reporter gene and *IL-24* therapeutic gene, respectively.



be expected that the transgene can be only expressed in tumor cells if oncolytic adenovirus is applied. To fully evaluate therapeutic potential of oncolytic adenoviral vector carrying this novel expression system, we have constructed novel double-controlled oncolytic adenovirus, in which 6.7K/gp19K of E3 genes was replaced with potent antitumor gene *mda-7/IL-24*.

Our previous and other studies have shown that *mda-7/IL-24* exerted strong antitumor activity by induction of tumor cell apoptosis, enhancement of immune responses, and inhibition of tumor angiogenesis (31–34).

Data presented here showed that expression of IL-24 could be detected at 6 h and became maximal expression at 48 h after




Fig. 2. Expression of transgene in cells after infection with oncolytic adenoviruses. Tumor cells (SW620 and BEL7404) and normal cells (QSG7701 and MRC5) were infected with AdCN205-IL-24, Ad-IL-24, or AdCN205-EGFP at a multiplicity of infection of 10. At different time points, the supernatant was collected for determination of IL-24 levels by ELISA. *A*, IL-24 level in cells infected with AdCN205-IL-24. *B*, IL-24 level in cells infected with Ad-IL-24. Columns, mean of three independent experiments; bars, SD. *C*, representative photomicrographs were obtained from BEL7404 and MRC5 infected with AdCN205-EGFP. Original magnification, $\times 200$.

infection in tumor cells. Treatment of the established tumors resulted in tumor regression. Our data showed that this novel AdCN205-IL-24 can provide potent and safe vector for the therapy of cancer.

Materials and Methods

Cell culture. Human hepatocellular carcinoma cell line (Hep3B), human colorectal carcinoma cell line (SW620), and human normal lung fibroblast cell lines (NHLF and MRC5) were obtained from the American Type Culture Collection. Human hepatocellular carcinoma cell lines (BEL7404 and SMMC7721) and human normal liver cell lines (QSG7701 and L-02) were purchased from the Shanghai Cell Collection. HEK293 was obtained from Microbix Biosystems, Inc. Cells were maintained in humidified 37°C atmosphere containing 5% CO₂ and cultured in DMEM (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 4 mmol/L glutamine, 50 units/mL penicillin, and 50 µg/mL streptomycin.

Virus construction and production. The constructs including pCN205-EGFP and pCN205-IL-24 were generated according to the standard molecular cloning protocol. The homologous recombination between pCN205-EGFP and pCN205-IL-24 plasmids and pCN103 plasmid carrying oncolytic adenoviral backbone was done in BJ5183 to create pAdCN205-EGFP and pAdCN205-IL-24, respectively. Viral particles were produced in HEK293 cells by transfection with *PacI*-digested pAdCN205-EGFP and pAdCN205-IL-24 to obtain recombinant AdCN205-EGFP and AdCN205-IL-24. All viruses were propagated and purified on a CsCl gradient using standard methods. The viruses were titered for viral particles using standard methods based on spectrophotometry at 260 nm. Functional titer (plaque-forming units) was determined with plaque assay on HEK293 cells according to the validated method developed by Quantum Biotechnology.

Viral progeny assay. To determine viral replication capacity, tumor or normal cells were infected with AdCN205-EGFP, AdCN205-IL-24, Ad-IL-24, AdCN103, or Ad-Wt at a multiplicity of infection of 5. Adenoviruses were removed after 6 h of infection. The cells were washed twice with PBS and incubated at 37°C for 48 h. The cellular pellets were lysed with three cycles of freeze thawing and the supernatant was collected. Viral titers were determined by plaque assay on HEK293 cells.

Cytotoxicity assay. Cells were plated in 96-well plates and treated with various adenoviruses. At the indicated times, medium was removed and fresh medium containing 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was added to each well. Cells were incubated at 37°C for 4 h, the medium was removed, and 100 µL DMSO was added and mixed thoroughly for 30 min. Absorbance was read on Tecan DNA Expert at 590 nm.

Detection of IL-24 by ELISA. The two-antibody sandwich ELISA was developed for detection of human mda-7/IL-24. The antibodies used are monoclonal mouse anti-human IL-24 antibody (R&D Systems), goat anti-human IL-24 antibody (R&D Systems), and peroxidase-conjugated rabbit anti-goat IgG (H&L). The absorbance was read at a 450-nm wavelength. The concentration of IL-24 was evaluated with standard curve.

Tumor xenograft in nude mice. Female BALB/c nude mice at 3 to 4 wk of age were obtained from Charles River Laboratories, Inc. and maintained at pathogen-free conditions. All procedures were done according to institutional guidelines and conformed to the NIH guidelines on the ethical use of animals. BEL7404 cells (2×10^6) were injected s.c. into flanks of mice. When the tumors had grown to 100 to 150 mm³, the animals were randomized into five groups. Each group was treated with either PBS or 2×10^8 plaque-forming units of vectors by intratumor injection every other day for 5 d. Tumors were measured twice weekly and tumor volume was calculated according to the following equation: $V \text{ (mm}^3\text{)} = \text{width}^2 \times \text{length} / 2$. Animal death was

documented. Animals were sacrificed when the diameter of the tumor reached 17 mm or when mean diameter is >15 mm.

Immunohistochemistry. Deparaffinized tumor sections were treated with goat monoclonal anti-IL-24 antibody (diluted 1:100; Santa Cruz Biotechnology). After incubation with anti-rabbit secondary antibody, IL-24 expression was detected with 3,3'-diaminobenzidine (Sigma) by enhancement with an avidin-biotin reaction ABC kit (Vector Laboratories). The slides were then counterstained with hematoxylin.

Statistical analysis. Statistical analyses were done with Student's *t* test to determine the significance. Pearson's χ^2 test was also used to test the hypothesis of no association of columns and rows in tabular data. $P < 0.05$ was considered significant.

Results

Constructions of oncolytic adenoviral vectors. Previously, we developed double-controlled oncolytic adenovirus AdCN103, in which hTERT promoter was used to control expression of mutant E1A without CR2 region (35). This vector allows a selective adenoviral replication in tumor cells harboring over-expression of hTERT and dysfunction of retinoblastoma. In the present study, we constructed a system, which allowed to substitute 6.7K/gp19K of E3 genes for the *EGFP* reporter gene (AdCN205-EGFP) and *mda-7/IL-24* gene (AdCN205-IL-24), respectively, so that expression of transgenes was driven by the endogenous E3 promoter. The structures of AdCN205-EGFP and AdCN205-IL-24 were shown in Fig. 1.

Expression of transgene in cells after infection with oncolytic adenoviral vectors. To show kinetics of IL-24 expression in the cells after infection with AdCN205-IL-24, we have infected tumor (SW620 and BEL7404) and normal (QSG7701 and MRC5) cells with AdCN205-IL-24. Our data showed that IL-24 could be detected at 6 h in tumor cells after infection. There was a steady increase of IL-24 expression up to 48 h,




Fig. 3. Selective replication of oncolytic adenoviral vector *in vitro*. Tumor cells (BEL7404, Hep3B, SMMC7721, and SW620) and normal cells (NHLF and QSG7701) were infected with AdCN205-EGFP, AdCN205-IL-24, Ad-IL-24, AdCN103, and Ad-Wt at a multiplicity of infection of 10. At 48 h after viral infection, cells and medium were harvested, and viral particles were released by three cycles of freezing and thawing. The viral titers were measured by plaque assay on HEK293 cells. Columns, mean of three independent experiments; bars, SD. pfu, plaque-forming unit.




Fig. 4. Cytotoxicity of oncolytic adenoviral vectors in tumor cells *in vitro*. Tumor cells (BEL7404, Hep3B, SMMC7721, and SW620) and normal cells (NHLF and L-02) were infected with AdCN205-EGFP, AdCN205-IL-24, Ad-IL-24, and Ad-Wt at a multiplicity of infection of 10. At different time points after infection, the cell survival was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Results were expressed as percentage of untreated control. Points, mean of three independent experiments; bars, SD.

and it was maintained at high level until 96 h after infection (Fig. 2A). In contrast, no IL-24 expression could be detected in normal cells until 72 h after infection because at this time point low level of IL-24 could be detected (Fig. 2A). However, similar kinetics and level of IL-24 expression were found in both tumor and normal cells infected with Ad-IL-24, in which IL-24 was controlled by cytomegalovirus promoter (Fig. 2B). The expression level of IL-24 was ~14 times higher in tumor cells infected with AdCN205-IL-24 than in tumor cells infected with Ad-IL-24. The high level of EGFP expression was only observed in tumor cells accompanied with cytopathic effect and no or low EGFP was observed in normal cells after infection with AdCN205-EGFP (Fig. 2C). The difference in kinetics and level of transgene expression may be due to viral replication induced by oncolytic adenoviral vectors in tumor cells.

Selective replication of oncolytic adenoviral vectors in vitro. The viral progeny assay was used to test whether the deletion of the E3 6.7K/gp19K and insertion of the *mda-7/IL-24* transgene altered the capacity of viral replication. As presented in Fig. 3, virus production by the AdCN205-EGFP and AdCN205-IL-24 was similar to that induced by AdCN103 and Ad-Wt in cancer cell lines. The virus production by Ad-IL-24 was significantly less than that induced by oncolytic adenoviruses in cancer cell lines. In contrast, virus production by the AdCN205-EGFP, AdCN205-IL-24, and AdCN103 in NHLF and QSG7701 normal cells was higher than that induced by Ad-IL-24 but much less than that of Ad-Wt. Thus, replacement of adenoviral E3 6.7K/gp19K gene with therapeutic gene *IL-24* or reporter gene *EGFP* does not interfere with adenoviral replication and production in tumor cell lines.

Cytotoxicity of oncolytic adenoviral vectors in tumor cells in vitro. To show the ability of the oncolytic adenovirus with therapeutic gene *mda-7/IL-24* to destroy tumor cells, we did cytotoxicity assay in the cells after infection with oncolytic adenoviruses. As shown in Fig. 4, replication-defective adenovirus Ad-IL-24 only induced minor cytotoxicity to the tumor cells, whereas AdCN205-EGFP or Ad-Wt induced obvious cytotoxicity. The cytotoxic effect of AdCN205-IL-24 on tumor cells was much more apparent than that induced by AdCN205-EGFP or Ad-Wt. In contrast, AdCN205-EGFP, AdCN205-IL-24, and Ad-IL-24 did not induce any cytotoxicity to normal cells. This result suggested that AdCN205-EGFP and AdCN205-IL-24 can selectively replicate in cancer cell lines and AdCN205-IL-24 displayed a powerful efficacy in killing cancer cells.

Antitumor activity of oncolytic adenoviral vectors in animal model with the established tumor. To know antitumor potency of oncolytic adenoviral vectors, we have treated the established tumors in an animal model by intratumoral injection of Ad-IL-24, AdCN205-EGFP, AdCN205-IL-24, and Ad-Wt. Our data showed that animals receiving PBS experienced progressive tumor growth. Treatment with Ad-IL-24 resulted in minor inhibition of tumor growth (Fig. 5A). Both AdCN205-EGFP and Ad-Wt exhibited strong antitumor activity at similar level. In contrast, treatment with AdCN205-IL-24 resulted in significant inhibition of tumor growth compared with that induced by AdCN205-EGFP and Ad-Wt ($P < 0.01$; Fig. 5A). Two of eight animals treated with AdCN205-IL-24 had complete tumor regression. Treatment with AdCN205-IL-24 resulted in long-term survival (Fig. 5B).

Immunocytochemical analysis has shown that expression of IL-24 was observed only in tumor sections from animals




Fig. 5. Antitumor activity of oncolytic adenoviral vectors in the established tumor in animal model. Tumors were established by injecting BEL7404 cells s.c. into the right flank of nude mice. The tumor-bearing animals were treated with either PBS or 2×10^8 plaque-forming units of different vectors by intratumoral injection. **A**, the size of tumor was measured twice weekly and tumor volume was calculated. Points, mean of tumor volume ($n = 8-10$); bars, SD. **B**, Kaplan-Meier survival.


treated with Ad-IL-24 and AdCN205-IL-24. The density of IL-24 expression was much higher in tumor sections from animals treated with AdCN205-IL-24 compared with that treated with Ad-IL-24 (Fig. 6). Pathologic analysis revealed that the necrotic area could be found in tumors treated with Ad-IL-24, whereas intensive necrotic area was observed in tumors treated with AdCN205-EGFP and Ad-Wt (Fig. 6). Treatment with AdCN205-IL-24 resulted in more intensive necrosis throughout tumor sections. The detection of adenoviral hexon expression has been evaluated in the liver sections from animals treated with Ad-IL-24, AdCN205-EGFP, AdCN205-IL-24, and Ad-Wt. Our data showed that expression of adenoviral hexon was only found in the liver sections from animals treated with Ad-Wt. No signal could be found in the liver sections treated with Ad-IL-24, AdCN205-EGFP, and AdCN205-IL-24 (Fig. 6). This study indicated that treatment of oncolytic adenoviral vectors did not induce viral replication in the normal tissues.

Discussion

Because cancer cells are genetically and phenotypically complex and frequently harbor multiple abnormalities (36), it is reasonable that single agent such as oncolytic adenovirus-alone is not sufficient for complete eradication of malignan-

cies. Arming oncolytic adenovirus with therapeutic genes has become an important issue in the war against cancers (11). Among different therapeutic genes, *IL-24* exerted strong anti-tumor activity. Clinical trial with replication-defective adenovirus expressing *IL-24* has shown a safe profile and some partial responses in patients with cancers (37, 38). Therefore, we chose

Fig. 6. Histologic analysis of tumor or liver sections from mice whose tumors were treated with PBS (A, F, and K), Ad-IL-24 (B, G, and L), Ad-Wt (C, H, and M), AdCN205-EGFP (D, I, and N), and AdCN205-IL-24 (E, J, and O). A to E, immunohistochemical staining for *mda-7/IL-24* protein in tumor sections (*brown staining*). Original magnification, $\times 400$. B and E, arrows, cells expressing IL-24. F to J, immunohistochemical staining for adenoviral hexon protein on the liver sections (*brown staining*). Original magnification, $\times 400$. The liver from mice treated with Ad-Wt (H) stained positive. K to O, H&E staining of tumor sections, indicating large areas of necrosis (nc) in tumors treated with Ad-Wt, AdCN205-EGFP, and AdCN205-IL-24. Original magnification, $\times 100$.



IL-24 as therapeutic gene in this newly constructed oncolytic adenovirus.

In the present work, we describe a dual gene therapy approach with a cancer cell-specific adenoviral replication and oncolysis and expression of apoptosis-inducing cytokine gene *IL-24*. Because transgene expression from the endogenous E3 native promoter was dependent on the viral replication, the tumor specificity of oncolytic adenovirus should be very important. So, we used double-controlled oncolytic adenovirus AdCN103, which targets TERT and retinoblastoma dysfunctions, for this purpose because our previous study has shown that it exerted restrictive viral replication in hepatocellular carcinoma tumor cells (35).

The most important issues of our new constructs would be that transgene could be expressed in a predicted manner and substitution of deleted E3 6.7K/gp19K with transgene could interfere with adenoviral replication. To answer these questions, we have determined transgene expression and viral progeny assay. Our data showed that IL-24 expression could be detected at 6 h, reached the maximal level at 48 h, and maintained the high level until 96 h after infection of tumor cells. The most important is that expression level of IL-24 is 14 times higher than that induced by cytomegalovirus promoter. However, only low level of IL-24 could be found in normal cells after 72 h of infection. In addition, there was no difference on virus production in tumor cells after infection with AdCN205-EGFP or AdCN205-IL-24. These data indicated that

our newly constructed oncolytic adenoviral vectors not only maintained their intrinsic capacity of viral replication in tumor cells but also induced high and sustained expression of therapeutic gene.

Our results indicated that AdCN205-IL-24 exerted much strong cytotoxicity to tumor cells compared with that induced by control vector AdCN205-EGFP or Ad-Wt. AdCN205-EGFP and Ad-Wt induced similar cytotoxicity to tumor cells. In contrast, both AdCN205-EGFP and AdCN205-IL-24 did not induce cytopathic effect to normal cells. In addition, our data further showed that a strong antitumor activity was observed in the animal model with the established tumors. These data indicated that incorporation of reporter gene into oncolytic adenovirus did not affect cytotoxicity and arming oncolytic adenovirus with therapeutic gene *IL-24* induced additional or synergistic antitumor activity. Recent studies have also shown that arming oncolytic adenovirus with suicide gene or cytokine gene can also significantly increase therapeutic index (12, 16, 17, 19).

In conclusion, we have successfully created adenoviral replication-based transgene expression system. Our data showed that expression of transgenes was restricted to tumor cells. The high level of expression of IL-24 and adenoviral replication greatly improved the oncolytic effects of this vector under both *in vitro* and *in vivo* conditions. These data indicated that this novel AdCN205-IL-24 can provide potent and safe vector for the therapy of cancers.

References

- Qian C, Sangro B, Prieto J. New strategies to enhance gene therapy efficiency. *Gastroenterology* 2002;123: 639–42.
- McCormick F. Cancer gene therapy: fringe or cutting edge? *Nat Rev Cancer* 2001;1:130–41.
- Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. *J Clin Oncol* 2004;22:1389–97.
- Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. *Clin Cancer Res* 2000;6:3395–9.
- Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. *Cell Res* 2006;16:182–8.
- Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. *Nat Med* 2001;7: 781–7.
- Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. *Mol Ther* 2006;14:107–17.
- Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Gene Ther* 2005;12:437–45.
- Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. *Clin Cancer Res* 2003;9: 555–61.
- Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 2000;6:879–85.
- Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. *Cancer Gene Ther* 2002;9: 1022–35.
- Bristol JA, Zhu M, Ji H, et al. *In vitro* and *in vivo* activities of an oncolytic adenoviral vector designed to express GM-CSF. *Mol Ther* 2003;7:755–64.
- Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. *Cancer Res* 2002;62:6089–98.
- Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. *Hum Gene Ther* 2005;16: 845–58.
- Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. *Cancer Res* 2001;61: 8743–50.
- Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. *Hepatology* 2004;39:1371–81.
- Liu XY, Qiu SB, Zou WG, et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. *Mol Ther* 2005;11:531–41.
- Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. *Gene Ther* 2002;9:168–75.
- Li X, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. *Clin Cancer Res* 2007; 13:5463–73.
- Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A. Induced apoptosis supports spread of adenovirus vectors in tumors. *Hum Gene Ther* 2001;12:1343–52.
- Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. *Cancer Gene Ther* 2003;10: 388–95.
- Yoder SS, Roberson BL, Leys EJ, et al. Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2. *Mol Cell Biol* 1983;3:819–28.
- Zhang Y, Schneider RJ. Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation of the cytokeleton network. *J Virol* 1994;68:2544–55.
- Rivera AA, Wang M, Suzuki K, et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site *in vitro* and *in vivo*. *Virology* 2004;320:121–34.
- Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, van Beusechem VW. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. *J Gene Med* 2005;7: 1053–62.
- Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. *Gene Ther* 2001;8:1123–31.
- Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. *Mol Ther* 2005;12:1052–63.
- Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW. Multigene expression from a replicating adenovirus using native viral promoters. *Mol Ther* 2003;7: 526–34.
- Young CS. The structure and function of the adenovirus major late promoter. *Curr Top Microbiol Immunol* 2003;272:213–49.

30. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. *Curr Top Microbiol Immunol* 1995;199:237–74.
31. Fisher PB, Gopalkrishnan RV, Chada S, et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. *Cancer Biol Ther* 2003;2:S23–37.
32. Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. mda-7/IL-24: exploiting cancer's Achilles' heel. *Mol Ther* 2005;11:4–18.
33. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. *J Immunol* 2002;168:6041–6.
34. Nishikawa T, Munshi A, Story MD, et al. Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells. *Oncogene* 2004;23:7125–31.
35. Zhang W, Cai R, Luo JJ, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy *in vitro* and *in vivo* for hepatocellular carcinoma. *Cancer Biol Ther* 2007;6:1726–32.
36. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557–76.
37. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. *Mol Ther* 2005;11:149–59.
38. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. *Mol Ther* 2005;11:160–72.

Clinical Cancer Research

Treatment of Cancer with a Novel Dual-Targeted Conditionally Replicative Adenovirus Armed with *mda-7/IL-24* Gene

Jingjing Luo, Qingmei Xia, Rui Zhang, et al.

Clin Cancer Res 2008;14:2450-2457.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/14/8/2450>

Cited articles This article cites 38 articles, 9 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/14/8/2450.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/14/8/2450.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/14/8/2450>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.